by Zaidel EJ, Forsyth CJ, Novick G, Marcus R, Ribeiro ALP, Pinazo MJ, Morillo CA, Echeverría LE, Shikanai-Yasuda MA, Buekens P, Perel P, Meymandi SK, Ralston K, Pinto F, Sosa-Estani S. Global Heart 2020;15(1): 69. doi: 10.5334/gh.891
Summary: The global COVID-19 pandemic is impacting vulnerable populations who already bear a heavy burden of neglected tropical disease. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19’s potential impact on the heart; additionally, the pandemic also affects treatment provision to people with acute or chronic indeterminate Chagas disease. The authors assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of Chagas disease. Based on the limited evidence available, they provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs.
